scholarly journals Nonhuman Adenoviral Vector-Based Platforms and Their Utility in Designing Next Generation of Vaccines for Infectious Diseases

Viruses ◽  
2021 ◽  
Vol 13 (8) ◽  
pp. 1493
Author(s):  
Marwa Alhashimi ◽  
Ahmed Elkashif ◽  
Ekramy E. Sayedahmed ◽  
Suresh K. Mittal
Keyword(s):  
Infectious Diseases ◽  
Immune Responses ◽  
Clinical Studies ◽  
Adenoviral Vector ◽  
Vaccine Delivery ◽  
Great Promise ◽  
Next Generation ◽  
Receptor Usage ◽  
Key Features ◽  
Preclinical And Clinical Studies

Several human adenoviral (Ad) vectors have been developed for vaccine delivery owing to their numerous advantages, including the feasibility of different vector designs, the robustness of elicited immune responses, safety, and scalability. To expand the repertoire of Ad vectors for receptor usage and circumvention of Ad vector immunity, the use of less prevalent human Ad types or nonhuman Ads were explored for vector design. Notably, many nonhuman Ad vectors have shown great promise in preclinical and clinical studies as vectors for vaccine delivery. This review describes the key features of several nonhuman Ad vector platforms and their implications in developing effective vaccines against infectious diseases.

scholarly journals Lipid Nanoparticles as Delivery Systems for RNA-Based Vaccines

Pharmaceutics ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 206 ◽  
Author(s):  
Basmah N. Aldosari ◽  
Iman M. Alfagih ◽  
Alanood S. Almurshedi
Keyword(s):  
Infectious Diseases ◽  
Immune Responses ◽  
Viral Vectors ◽  
Cost Effective ◽  
Lipid Nanoparticles ◽  
Target Cells ◽  
Efficient Delivery ◽  
Preclinical And Clinical Studies ◽  
Cancer Immunotherapies ◽  
Conventional Vaccine

There has been increased interest in the development of RNA-based vaccines for protection against various infectious diseases and also for cancer immunotherapies. Rapid and cost-effective manufacturing methods in addition to potent immune responses observed in preclinical and clinical studies have made mRNA-based vaccines promising alternatives to conventional vaccine technologies. However, efficient delivery of these vaccines requires that the mRNA be protected against extracellular degradation. Lipid nanoparticles (LNPs) have been extensively studied as non-viral vectors for the delivery of mRNA to target cells because of their relatively easy and scalable manufacturing processes. This review highlights key advances in the development of LNPs and reviews the application of mRNA-based vaccines formulated in LNPs for use against infectious diseases and cancer.

Disulfiram: A repurposed drug in preclinical and clinical development for the treatment of infectious diseases

2022 ◽  
Vol 20 ◽  
Author(s):  
Marco Custodio ◽  
Jennifer Sparks ◽  
Timothy E. Long
Keyword(s):  
Lyme Disease ◽  
Infectious Diseases ◽  
Antimicrobial Agent ◽  
Clinical Studies ◽  
Clinical Development ◽  
Parasitic Diseases ◽  
Hiv Latency ◽  
Preclinical Research ◽  
Reversal Agent ◽  
Preclinical And Clinical Studies

Abstract: This article reviews preclinical and clinical studies on the repurposed use of disulfiram (Antabuse) as an antimicrobial agent. Preclinical research covered on the alcohol sobriety aid include uses as an anti-MRSA agent, a carbapenamase inhibitor, antifungal drug for candidiasis, and a treatment for parasitic diseases due to protozoa (e.g., giardiasis, leishmaniasis, malaria) and helminthes (e.g., schistosomiasis, trichuriasis). Past, current, and pending clinical studies on disulfiram as a post-Lyme disease syndrome (PTLDS) therapy, an HIV latency reversal agent, and an intervention for COVID-19 infections are also reviewed.

Two way relationship of pregnancy and immune responses to infectious diseases

Placenta ◽  
1996 ◽  
Vol 17 (5-6) ◽  
pp. A10
Author(s):  
L. Krishnan ◽  
L.J. Guilbert ◽  
T.G. Wegmann ◽  
M. Belosevic ◽  
T.R. Mosmann
Keyword(s):  
Infectious Diseases ◽  
Immune Responses ◽  
Relationship Of

scholarly journals Next generation methodology for updating HA vaccines against emerging human seasonal influenza A(H3N2) viruses

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
James D. Allen ◽  
Ted M. Ross
Keyword(s):  
Influenza Virus ◽  
Immune Responses ◽  
Influenza A ◽  
Seasonal Influenza ◽  
Influenza Viruses ◽  
Next Generation ◽  
Virus Infections ◽  
Wild Type ◽  
Influenza Hemagglutinin ◽  
H3n2 Influenza

AbstractWhile vaccines remain the best tool for preventing influenza virus infections, they have demonstrated low to moderate effectiveness in recent years. Seasonal influenza vaccines typically consist of wild-type influenza A and B viruses that are limited in their ability to elicit protective immune responses against co-circulating influenza virus variant strains. Improved influenza virus vaccines need to elicit protective immune responses against multiple influenza virus drift variants within each season. Broadly reactive vaccine candidates potentially provide a solution to this problem, but their efficacy may begin to wane as influenza viruses naturally mutate through processes that mediates drift. Thus, it is necessary to develop a method that commercial vaccine manufacturers can use to update broadly reactive vaccine antigens to better protect against future and currently circulating viral variants. Building upon the COBRA technology, nine next-generation H3N2 influenza hemagglutinin (HA) vaccines were designed using a next generation algorithm and design methodology. These next-generation broadly reactive COBRA H3 HA vaccines were superior to wild-type HA vaccines at eliciting antibodies with high HAI activity against a panel of historical and co-circulating H3N2 influenza viruses isolated over the last 15 years, as well as the ability to neutralize future emerging H3N2 isolates.

scholarly journals Toxic Animal-Based Medicinal Materials Can Be Effective in Treating Endometriosis: A Scoping Review

Toxins ◽  
2021 ◽  
Vol 13 (2) ◽  
pp. 145
Author(s):  
Su-In Hwang ◽  
Young-Jin Yoon ◽  
Soo-Hyun Sung ◽  
Ki-Tae Ha ◽  
Jang-Kyung Park
Keyword(s):  
Side Effects ◽  
Clinical Studies ◽  
Malignant Tumors ◽  
Experimental Studies ◽  
Herbal Medicines ◽  
Treatment Method ◽  
Reproductive Age ◽  
Dependent Growth ◽  
Gynecological Disorder ◽  
Preclinical And Clinical Studies

Animal toxins and venoms have recently been developed as cancer treatments possessing tumor cell growth-inhibitory, antiangiogenesis, and proapoptotic effects. Endometriosis is a common benign gynecological disorder in reproductive-age women, and no definite treatment for this disorder is without severe side effects. As endometriosis and malignant tumors share similar characteristics (progressive, invasive, estrogen-dependent growth, and recurrence), animal toxins and venoms are thought to be effective against endometriosis. The objective of this study was to outline studies using toxic animal-based medicinal materials (TMM) as endometriosis treatment and to explore its clinical applicability. Preclinical and clinical studies using TMM were searched for in four databases from inception to October 2020. A total of 20 studies of TMM on endometriosis were included. In eight clinical studies, herbal medicines containing TMM were effective in relieving symptoms of endometriosis, with no side effects. In twelve experimental studies, the main therapeutic mechanisms of TMM against endometriosis were proapoptotic, antiangiogenesis, estrogen level-reducing, and possible anti-inflammatory effects. TMM are thus considered promising sources for the development of an effective treatment method for endometriosis. Further studies are needed to clarify the therapeutic mechanism of TMM against endometriosis and to provide sufficient grounds for clinical application.

Sign in / Sign up

Export Citation Format

Share Document